LT3377637T - Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose - Google Patents

Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose

Info

Publication number
LT3377637T
LT3377637T LTEP16826873.8T LT16826873T LT3377637T LT 3377637 T LT3377637 T LT 3377637T LT 16826873 T LT16826873 T LT 16826873T LT 3377637 T LT3377637 T LT 3377637T
Authority
LT
Lithuania
Prior art keywords
wounds
disorders
diseases
skin
compositions
Prior art date
Application number
LTEP16826873.8T
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Original Assignee
Krystal Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3377637(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech, Inc. filed Critical Krystal Biotech, Inc.
Publication of LT3377637T publication Critical patent/LT3377637T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
LTEP16826873.8T 2016-04-08 2016-12-28 Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose LT3377637T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08
PCT/US2016/068974 WO2017176336A1 (en) 2016-04-08 2016-12-28 Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

Publications (1)

Publication Number Publication Date
LT3377637T true LT3377637T (lt) 2020-07-10

Family

ID=57822104

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16826873.8T LT3377637T (lt) 2016-04-08 2016-12-28 Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose

Country Status (21)

Country Link
US (7) US9877990B2 (lt)
EP (2) EP3377637B1 (lt)
JP (3) JP6970086B2 (lt)
KR (1) KR20180128016A (lt)
CN (1) CN109072255A (lt)
AU (3) AU2016401692B2 (lt)
CA (1) CA3017487A1 (lt)
CL (3) CL2018002814A1 (lt)
CY (1) CY1123024T1 (lt)
DK (1) DK3377637T3 (lt)
ES (1) ES2796488T3 (lt)
HR (1) HRP20200853T1 (lt)
HU (1) HUE049237T2 (lt)
LT (1) LT3377637T (lt)
MX (2) MX2018012135A (lt)
PL (1) PL3377637T3 (lt)
PT (1) PT3377637T (lt)
RS (1) RS60410B1 (lt)
SG (1) SG11201808314QA (lt)
SI (1) SI3377637T1 (lt)
WO (1) WO2017176336A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PL3377637T3 (pl) * 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
US10864153B2 (en) * 2016-11-14 2020-12-15 The Regents Of The University Of Michigan Compositions and methods for blocking ultraviolet radiation
EP3568474A1 (en) 2017-01-10 2019-11-20 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) * 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
WO2020068862A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
EP3856914A1 (en) * 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
JPWO2020149395A1 (ja) * 2019-01-18 2021-11-25 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
AU2020219343A1 (en) 2019-02-08 2021-08-19 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
TWI818166B (zh) * 2019-03-27 2023-10-11 美商菲尼克斯組織修復公司 用於生產膠原蛋白7組合物之系統及方法
AU2020341451A1 (en) 2019-09-03 2022-03-24 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
WO2023064806A1 (en) 2021-10-12 2023-04-20 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
ATE388720T1 (de) * 1997-04-10 2008-03-15 Univ Southern California Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
EP1083951A4 (en) * 1998-06-12 2004-07-07 Aradigm Corp METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY
CA2356937A1 (en) 1998-12-31 2000-07-13 Richard J. Whitley Recombinant herpes simplex virus useful for treating neoplastic disease
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
CA2430341A1 (en) * 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2006050211A2 (en) * 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2006079014A2 (en) * 2005-01-21 2006-07-27 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
US9340783B2 (en) * 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CA2873881A1 (en) * 2012-05-18 2013-11-21 Stephen Bruce Fleming Combination treatments and compositions for wound healing
JP6480874B2 (ja) * 2013-03-01 2019-03-13 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタＲｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｎｎｅｓｏｔａ Ｔａｌｅｎに基づく遺伝子修正
PL2968586T3 (pl) * 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
US10174341B2 (en) 2013-07-17 2019-01-08 University of Pittsburgh—of the Commonwealth System of Higher Education Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
JP6588024B2 (ja) * 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
KR20220100078A (ko) 2014-01-31 2022-07-14 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
CN113559246A (zh) * 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
US20180148711A1 (en) * 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
WO2017106202A2 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
ES2924521T3 (es) * 2016-03-25 2022-10-07 Periphagen Inc Vectores del VHS para la administración de NT3, y tratamiento de la CIPN
DK3432912T3 (da) * 2016-03-25 2023-03-13 Periphagen Inc Hsv-vektorer med høj transduktion
PL3377637T3 (pl) 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
AU2019292580A1 (en) 2018-06-29 2021-02-04 Krystal Biotech, Inc. Compositions and methods for antibody delivery

Also Published As

Publication number Publication date
KR20180128016A (ko) 2018-11-30
US20200101123A1 (en) 2020-04-02
US11865148B2 (en) 2024-01-09
CL2023000743A1 (es) 2023-09-29
SI3377637T1 (sl) 2020-08-31
JP2023118838A (ja) 2023-08-25
CY1123024T1 (el) 2021-10-29
AU2022204729A1 (en) 2022-07-21
RS60410B1 (sr) 2020-07-31
EP3377637A1 (en) 2018-09-26
AU2016401692A1 (en) 2018-09-27
US20170290866A1 (en) 2017-10-12
EP3377637B1 (en) 2020-03-18
HRP20200853T1 (hr) 2020-08-21
WO2017176336A1 (en) 2017-10-12
NZ746213A (en) 2021-08-27
US10441614B2 (en) 2019-10-15
US20230149486A1 (en) 2023-05-18
US20220273737A1 (en) 2022-09-01
ES2796488T3 (es) 2020-11-27
JP2019513689A (ja) 2019-05-30
PT3377637T (pt) 2020-06-17
US20190160122A1 (en) 2019-05-30
AU2016401692B2 (en) 2019-10-03
MX2022006072A (es) 2022-06-14
DK3377637T3 (da) 2020-05-18
SG11201808314QA (en) 2018-10-30
US9877990B2 (en) 2018-01-30
JP6970086B2 (ja) 2021-11-24
AU2019280069B2 (en) 2022-04-07
AU2019280069A1 (en) 2020-01-16
JP7480105B2 (ja) 2024-05-09
US10155016B2 (en) 2018-12-18
MX2018012135A (es) 2019-03-28
EP3712273A1 (en) 2020-09-23
HUE049237T2 (hu) 2020-09-28
US20230414686A1 (en) 2023-12-28
CL2021000881A1 (es) 2021-09-10
CL2018002814A1 (es) 2019-02-15
PL3377637T3 (pl) 2020-09-07
US11185564B2 (en) 2021-11-30
CA3017487A1 (en) 2017-10-12
JP2022023174A (ja) 2022-02-07
US20180169160A1 (en) 2018-06-21
CN109072255A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
EP3448398A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
EP3337465A4 (en) Compositions and methods of use in combination for the treatment and diagnosis of autoimmune diseases
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
EP3268007A4 (en) Compositions and therapeutic methods for the treatment of complement-associated diseases
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
EP3185862A4 (en) PROTECTIVE METALOTHION ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES
SI3307277T1 (sl) Enoverižni oligonukleotidi za uporabo pri zdravljenju motenj kože
IL246855A0 (en) Materials for use in the treatment of retinitis
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
IL270978B (en) Grape skin for use in the treatment of dysbiosis
EP3302464A4 (en) USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
AU2016900442A0 (en) PAK1-blocking esters, preparation, and their use in treatment of cancer and other PAK1-dependent diseases/disorders
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases